Patterns and predictors of lipid-lowering therapy in patients with atherosclerotic cardiovascular disease and/or diabetes mellitus in 2014: Insights from a large US managed-care population

Clinical Cardiology

Volumn 40, Issue 3, 2017, Pages 155-162

  Steen, Dylan L ^a   Khan, Irfan ^b   Becker, Laura ^c   Foody, JoAnne M ^d   Gorcyca, Katherine ^b   Sanchez, Robert J ^e   Giugliano, Robert P ^d  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b SANOFI   (France)

^c OPTUM   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

coronary disease; diabetes mellitus; lipid lowering therapy; peripheral vascular disease; stroke

Indexed keywords

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BRAIN ISCHEMIA; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PATIENT CARE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRACTICE GUIDELINE; PRESCRIPTION; RETROSPECTIVE STUDY; RISK FACTOR; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFECTS; FOLLOW UP; HEALTH INSURANCE; INCIDENCE; MIDDLE AGED; MULTICENTER STUDY; PROGNOSIS; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA; UNITED STATES;

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AGED; ATHEROSCLEROSIS; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 85008490325     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22641     Document Type: Article

References (32)

1. Baigent C, Blackwell L, Emberson J, et al; Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681.
2. Mihaylova B, Emberson J, Blackwell L, et al; Cholesterol Treatment Trialists’ (CTT) Collaboration. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–590.
3. Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation. 2006;114:2788–2797.
4. Rosenson RS, Kent ST, Brown TM, et al. Underutilization of high-intensity statin therapy after hospitalization for coronary heart disease. J Am Coll Cardiol. 2015;65:270–277.
5. Wong ND, Young D, Zhao Y, et al. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011–2012. J Clin Lipidol. 2016;10:1109–1118.
6. Johansen ME, Green LA, Sen A, et al. Cardiovascular risk and statin use in the United States. Ann Fam Med. 2014;12:215–223.
7. Maddox TM, Borden WB, Tang F, et al. Implications of the 2013 ACC/AHA cholesterol guidelines for adults in contemporary cardiovascular practice: insights from the NCDR PINNACLE registry. J Am Coll Cardiol. 2014;64:2183–2192.
8. Stark Casagrande S, Fradkin JE, Saydah SH, et al. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988–2010. Diabetes Care. 2013;36:2271–2279.
9. Pande RL, Perlstein TS, Beckman JA, et al. Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004. Circulation. 2011;124:17–23.
10. Ovbiagele B, Schwamm LH, Smith EE, et al. Recent nationwide trends in discharge statin treatment of hospitalized patients with stroke. Stroke. 2010;41:1508–1513.
11. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295:180–189.
12. Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1—full report. J Clin Lipidol. 2015;9:129–169.
13. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association [published corrections available at http://circ.ahajournals.org/content/131/4/e29.full]. Circulation. 2015;131:e29–e322.
14. Adedinsewo D, Taka N, Agasthi P, et al. Prevalence and factors associated with statin use among a nationally representative sample of US adults: National Health and Nutrition Examination Survey, 2011–2012. Clin Cardiol. 2016;39:491–496.
15. Shah NS, Huffman MD, Ning H, et al. Trends in vascular risk factor treatment and control in US stroke survivors: the National Health and Nutrition Examination Surveys (1999–2010). Circ Cardiovasc Qual Outcomes. 2013;6:270–277.
16. Abdallah MS, Kosiborod M, Tang F, et al. Patterns and predictors of intensive statin therapy among patients with diabetes mellitus after acute myocardial infarction. Am J Cardiol. 2014;113:1267–1272.
17. Arnold SV, Kosiborod M, Tang F, et al. Patterns of statin initiation, intensification, and maximization among patients hospitalized with an acute myocardial infarction. Circulation. 2014;129:1303–1309.
18. Arnold SV, Spertus JA, Masoudi FA, et al. Beyond medication prescription as performance measures: optimal secondary prevention medication dosing after acute myocardial infarction [published correction appears in J Am Coll Cardiol. 2013;63:944]. J Am Coll Cardiol. 2013;62:1791–1801.
19. Javed U, Deedwania PC, Bhatt DL, et al. Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: an analysis of 65 396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG). Am Heart J. 2010;160:1130–1136.
20. Choudhry NK, Avorn J, Glynn RJ, et al; MI-FREEE Trial. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011;365:2088–2097.
21. Maningat P, Gordon BR, Breslow JL. How do we improve patient compliance and adherence to long-term statin therapy? Curr Atheroscler Rep. 2013;15:291.
22. Brown DW, Anda RF, Felitti VJ. Self-reported information and pharmacy claims were comparable for lipid-lowering medication exposure. J Clin Epidemiol. 2007;60:525–529.
23. Asch DA, Troxel AB, Stewart WF, et al. Effect of financial incentives to physicians, patients, or both on lipid levels: a randomized clinical trial. JAMA. 2015;314:1926–1935.
24. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published corrections appear in J Am Coll Cardiol. 2014;63(25 part B):3024–3025 and 2015;66:2812]. J Am Coll Cardiol. 2014;63(25 part B):2889–2934.
25. Silver SpringMDFDA approves first version of cholesterol-lowering drug lipitor [press release]. : US Food and Drug Administration; March 10, 2014. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm281817.htm. Accessed September 2016.
26. US Food and Drug Administration. First generic drug approvals. http://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/drugandbiologicapprovalreports/andagenericdrugapprovals/default.htm. Accessed September 2016.
27. Tran JN, Caglar T, Stockl KM, et al. Impact of the new ACC/AHA guidelines on the treatment of high blood cholesterol in a managed care setting [published correction appears in Am Health Drug Benefits. 2014;7:487–488]. Am Health Drug Benefits. 2014;7:430–443.
28. Pencina MJ, Navar-Boggan AM, D'Agostino RB Sr, et al. Application of new cholesterol guidelines to a population-based sample. N Engl J Med. 2014;370:1422–1431.
29. Pokharel Y, Akeroyd JM, Ramsey DJ, et al. Statin use and its facility-level variation in patients with diabetes: insight from the Veterans Affairs National Database. Clin Cardiol. 2016;39:185–191.
30. Virani SS, Woodard LD, Akeroyd JM, et al. Is high-intensity statin therapy associated with lower statin adherence compared with low- to moderate-intensity statin therapy? Implications of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guidelines. Clin Cardiol. 2014;37:653–659.
31. Cannon CP, on behalf of IMPROVE-IT Investigators. A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation. 2014;130:2105–2126.
32. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2016 ACC Expert Consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2016;68:92–125.